If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The yankies appear to like it very much!
We have no idea of the price ? this is a bookbuid ? anyone been invited ?
Hey, minimum fair value I see at £9 for a reasonable market cap based on historical revenues. Average fair value I see at £12 given certainty of income for the year ahead. About £30 minimum in a partner has a ex vivo full approval. Imo
Where do people see fair value on this share?
Once it hits nasdaq, in general americans seem to be much more aggressive in investing in business on future scope, which Maxcyte has the upside on.
Just in case you haven’t seen it. Have watched it a few times - very compelling case for being invested here.
https://youtu.be/sY4TtXq57As
Strong day today. Market taking the RNS well.
blimey - they are buys rather than sells! me finks
Seems like a fund is unloading big chunks in recent days and reducing stake - despite the SP rise.
The article speculates that a Nasdaq listing is the catalyst to drive the share price higher. With the Special Meeting later today, that catalyst may soon come to fruition.
--
Questor share tip: MaxCyte offers huge potential but it may take a new listing on Nasdaq to get the share price higher still
This article was posted in May so don’t really understand linking to it now. Until the NASDAQ listing occurs or there is a significant new customer nothing will change
Price action getting interesting.
https://www.telegraph.co.uk/investing/shares/questor-special-company-list-investors-will-besotted/
https://investors.maxcyte.com/news-events/documents-presentations
Cheers - thanks for that Bull.Bear
Carma is not on hold - it has been moved to a licencing model, (as per the “electroporation” machines). So Maxcyte will provide the tools and processes for treatments, but won't develop the actual treatments, (which is a lengthy and extremely costly process that carries a large amount of risk).
Also:
https://www.telegraph.co.uk/investing/shares/questor-special-company-list-investors-will-besotted/
Cheers Nick - thought they put the CARMA programme on hold tho?
Scoobydoo - The connection is:
MXCT are developing CARMA, its platform for immuno-oncology to rapidly develop chimeric antigen receptor (CAR) therapies for a broad range of cancer indications including solid tumours where existing CAR-T approaches face challenges
@Jones - I was wondering whether there would be a connection to MXCT after reading this article - what is the connection Jones?
Value getting nicely baked in. Clearly an extremely high anticipation of the treatment being approved if $900m is being paid up front.
Results , Tuesday 20 April, also analysts conference call @ 2pm.
I reckon MXCT is being bombarded left right and centre by smaller companies wanting MXCT to sell / use their tech to top pharmas. The CEO alluded to the strong partnerships with the top pharma companies. Given MXCT's super strong trusted position, going on an acquisition spree at very reasonable costs for acquirees providing cutting edge tech can only be earnings accretive.
@Silentnight - based on last year - should be sometime in late part of April